PYPD · NASDAQ · Biotechnology

PolyPid (PYPD)

Develops local prolonged-release therapies led by D-PLEX100 for surgical-site infection prevention.

$5.28
At close−0.05 (−0.94%)

Something off on this page? Send us feedback.

Next report
Nov 11, 2026
in 69 days
EPS estimate
−$0.38
Revenue estimate
$800.0K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$1.13−$0.70−$0.78−$0.37−$0.41−$0.35−$0.35Pending
Estimate−$0.90−$0.80−$0.53−$0.54−$0.34−$0.47−$0.38−$0.38
Surprise−25.6%+12.5%−47.2%+31.5%−20.6%+25.5%+7.3%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
ReportedPending
Estimate$300.0K$800.0K
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.38
Aug 2026−$0.38−$0.35+7.3%
May 2026−$0.47−$0.35+25.5%
Feb 2026−$0.34−$0.41−20.6%
Nov 2025−$0.54−$0.37+31.5%

The latest year is open to everyone — the 28 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Feb 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Nov 2021
Aug 2021
May 2021
Feb 2021
Nov 2020
Aug 2020
Jun 2020
Feb 2020
Dec 2019
Jun 2019
Mar 2019
Dec 2017
Sep 2017
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 11, 2026−$0.38$800.0K
Aug 12, 2026−$0.38−$0.35+7.3%$300.0K+2.3%
May 13, 2026−$0.47−$0.35+25.5%+3.8%
Feb 11, 2026−$0.34−$0.41−20.6%−0.7%
Nov 12, 2025−$0.54−$0.37+31.5%−4.5%

The latest year is open to everyone — the 28 quarters behind it read with an account.

Sign in
Aug 13, 2025
May 14, 2025
Feb 12, 2025
Nov 13, 2024
Aug 14, 2024
May 8, 2024
Feb 14, 2024
Nov 8, 2023
Aug 9, 2023
May 10, 2023
Feb 8, 2023
Nov 9, 2022
Aug 10, 2022
May 11, 2022
Feb 9, 2022
Nov 10, 2021
Aug 11, 2021
May 12, 2021
Feb 10, 2021
Nov 11, 2020
Aug 19, 2020
Jun 29, 2020
Feb 24, 2020
Dec 31, 2019
Jun 30, 2019
Mar 31, 2019
Dec 31, 2017
Sep 30, 2017